Febrile neutropenia (FN) is an oncologic emergency defined as a single oral temperature ≥38.3°C (101°F) or ≥38.0°C (100.4°F) sustained over 1 hour in a patient with an ANC <500 cells/mcL (or <1,000 cells/mcL with predicted decline to ≤500 within 48 hours). [1-2] Empiric broad-spectrum antibiotics must be administered within 1 hour of presentation. [3-4] The mortality rate ranges up to 11%, and in septic shock may reach 50%. [3]
1. History
- Key HPI questions: Type of cancer, chemotherapy regimen, date of last cycle (highest risk within 6 weeks), prior episodes of FN, prior infections and organisms, current prophylactic antibiotics [2-3]
- Symptom characterization: Fever pattern (single spike vs. sustained), rigors/chills, malaise, myalgias
- Timing: Nadir typically 7–14 days post-chemotherapy for solid tumors; may be prolonged (>14 days) in hematologic malignancies [4]
- Associated symptoms: Oral pain/mucositis, odynophagia, cough, dyspnea, abdominal/perirectal pain, diarrhea, dysuria, skin lesions, catheter site changes [2]
- Important negatives: Absence of localizing symptoms is common — neutropenic patients often lack classic inflammatory signs (no purulence, minimal erythema, no infiltrate on CXR) [1]
2. Alarm Features
- Hemodynamic instability: Hypotension (SBP <90 mmHg), tachycardia, altered mental status → sepsis/septic shock
- Respiratory distress: Hypoxia, tachypnea → pneumonia, ARDS
- Severe mucositis (grade 3–4): Inability to swallow, risk of bacteremia from mucosal translocation [2]
- Perirectal abscess/cellulitis: Avoid rectal exams/suppositories; high risk of polymicrobial bacteremia
- CNS symptoms: Headache, neck stiffness, focal deficits → meningitis/encephalitis [2]
- Tunnel infection or port pocket infection: Requires catheter removal [2]
- Prolonged neutropenia (ANC ≤100 for ≥7 days): High risk for invasive fungal infection [2]
3. Medications
Empiric antibiotics (high-risk, inpatient IV monotherapy — all NCCN Category 1): [2]
- Cefepime 2 g IV q8h
- Meropenem 1–2 g IV q8h
- Piperacillin-tazobactam 4.5 g IV q6h
- Imipenem/cilastatin 500 mg IV q6h
- Ceftazidime 2 g IV q8h (category 2B — weak Gram-positive coverage)
Low-risk outpatient oral regimens: [2]
- Ciprofloxacin 750 mg PO q12h + amoxicillin/clavulanate 875/125 mg PO q12h (category 1)
- Moxifloxacin 400 mg PO daily (category 1; lacks Pseudomonas coverage)
- Levofloxacin 750 mg PO daily
- Not recommended if patient was on prior fluoroquinolone prophylaxis
When to add vancomycin: [2-3]
- Hemodynamic instability, cellulitis, catheter-site infection, MRSA risk, positive Gram-positive cultures
- Vancomycin is not part of standard initial empiric therapy
Severe beta-lactam allergy: Vancomycin + aztreonam with ID/allergy consultation [2]
Contraindicated/cautions
- Avoid rectal medications (suppositories, enemas)
- NSAIDs may mask fever — use with caution
- G-CSF should be avoided in patients with acute leukemia or MDS [4]
4. Diet
- Neutropenic diet (low-microbial diet): Historically recommended but evidence is limited; many institutions are moving away from strict restrictions
- Avoid raw/undercooked meats, unpasteurized dairy, unwashed raw fruits/vegetables
- Hydration: Aggressive IV hydration if dehydrated or unable to tolerate PO; dehydration is a high-risk feature on MASCC scoring [2]
- Long-term: Ensure adequate caloric intake, especially with mucositis
5. Review of Systems
- HEENT: Oral ulcers, thrush, sinus pain/congestion, sore throat
- Respiratory: Cough, dyspnea, pleuritic chest pain
- GI: Nausea/vomiting, diarrhea (C. difficile risk), abdominal pain, perirectal pain/swelling
- GU: Dysuria, frequency, flank pain
- Skin: New rashes, vesicular lesions (HSV/VZV), catheter site erythema/drainage
- Neuro: Headache, confusion, neck stiffness, focal deficits
- MSK: Bone pain (may suggest marrow recovery or G-CSF effect)
6. Collateral History and Family History
- Collateral: Confirm chemotherapy regimen and timing with oncologist; review prior culture data and resistance patterns; verify prophylactic medications; confirm G-CSF use
- Social context: Home environment adequacy for outpatient management (caregiver availability, proximity to hospital, telephone access, compliance history) [3]
- Family history: Generally not contributory in chemotherapy-induced FN; relevant in congenital/cyclic neutropenia (autosomal dominant ELANE mutations, autosomal recessive Kostmann syndrome) [4]
7. Risk Factors
- Chemotherapy type: Highest risk with AML induction, high-dose cytarabine, allogeneic HCT [2]
- Duration of neutropenia: ANC ≤100 for ≥7 days = high risk [2]
- Hematologic malignancy > solid tumor
- Age >65 years
- Comorbidities: COPD, hepatic insufficiency (AST/ALT >5× ULN), renal insufficiency (CrCl <30 mL/min) [2]
- Uncontrolled/progressive cancer (leukemia not in remission, progression after ≥2 cycles) [2]
- Prior MDRO colonization or infection [2]
- Mucositis grade 3–4, indwelling catheters, prior FN episodes
- Inpatient status at fever onset [2]
8. Differential Diagnosis
- Bacterial infection (most common concern): Bacteremia, pneumonia, UTI, skin/soft tissue, intra-abdominal, C. difficile colitis
- Fungal infection: Invasive aspergillosis, candidiasis — consider after ≥4–7 days of persistent fever on antibiotics [2][5]
- Viral infection: HSV reactivation, VZV, CMV, respiratory viruses (influenza, RSV, COVID-19) [3]
- Drug fever: Chemotherapy agents, G-CSF, blood products
- Tumor fever: Especially in hematologic malignancies
- Thromboembolism: PE/DVT can present with fever
- Transfusion reaction
- Cannot-miss: Typhlitis (neutropenic enterocolitis), perirectal abscess, necrotizing fasciitis, meningitis
9. Past Medical History
- Prior episodes of FN and outcomes
- Prior documented infections and antimicrobial susceptibilities
- MDRO colonization status (MRSA, VRE, ESBL, CRE)
- Prior fungal infections (affects MASCC scoring and prophylaxis) [2]
- Chronic conditions: COPD, diabetes, hepatic/renal disease
- Surgical history: Splenectomy (encapsulated organism risk), prior catheter infections
- Immunosuppressive medications beyond chemotherapy (corticosteroids, biologics)
10. Physical Exam
- Vitals: Temperature, HR, BP, RR, SpO2 — hemodynamic instability is a critical finding
- Oropharynx: Mucositis, thrush, ulcers, dental infections
- Lungs: Often clear despite pneumonia in neutropenic patients; crackles or decreased breath sounds are significant
- Abdomen: RLQ tenderness (typhlitis), diffuse tenderness, peritoneal signs
- Perianal area: Erythema, tenderness, fluctuance — visual inspection only; avoid digital rectal exam [1]
- Skin: Cellulitis, ecthyma gangrenosum (Pseudomonas), vesicular lesions (HSV/VZV), catheter exit sites
- Central line sites: Erythema, drainage, tunnel tenderness, port pocket swelling [2]
- Pearl: Physical exam findings are often muted due to absent neutrophilic inflammatory response [1]
11. Lab Studies
Initial labs: [2-3]
- CBC with differential (confirm ANC)
- Comprehensive metabolic panel (BUN, creatinine, electrolytes, LFTs, bilirubin)
- Lactate
- Blood cultures: ≥2 sets (one peripheral + one from each catheter lumen) [3]
- Urinalysis and urine culture (if symptomatic)
- C. difficile assay (if diarrhea)
Additional as indicated
- Procalcitonin (may help guide de-escalation)
- Coagulation studies (if DIC suspected)
- Galactomannan, beta-D-glucan (if prolonged neutropenia or suspected fungal infection) [2]
- Respiratory viral panel (if respiratory symptoms)
Expected abnormalities: Leukopenia with low ANC; may see elevated lactate, transaminitis, or renal dysfunction in sepsis
12. Imaging
- Chest X-ray: First-line if respiratory symptoms; may be falsely negative in neutropenic patients (lack of inflammatory infiltrate) [3]
- CT chest: Gold standard for pulmonary infiltrates; consider early if CXR negative but clinical suspicion high; halo sign suggests invasive aspergillosis [2]
- CT abdomen/pelvis: If abdominal pain — evaluate for typhlitis, abscess, appendicitis
- CT sinuses: If facial pain/congestion — evaluate for invasive fungal sinusitis
- MRI brain: Preferred over CT for CNS symptoms [2]
- Imaging unnecessary: In uncomplicated FN without localizing symptoms, routine imaging beyond CXR is not required
13. Special Tests
Risk stratification scores: [2]
The MASCC Risk Index is the most widely validated tool for identifying low-risk patients (score ≥21 = low risk; <21 = high risk):
The CISNE score is an alternative validated in patients with solid tumors and "apparently stable" FN episodes (score ≥3 = high risk). [2]
The NCCN risk assessment algorithm is shown below:
Point-of-care tests: Bedside lactate, blood glucose (stress hyperglycemia is a CISNE criterion)
14. ECG
- Indications: Hemodynamic instability, sepsis, electrolyte abnormalities, chest pain, pre-existing cardiac disease
- Findings to watch for: Sinus tachycardia (sepsis), new arrhythmias, QTc prolongation (fluoroquinolones, azoles, ondansetron), ST changes (demand ischemia in sepsis)
- Not routinely required in uncomplicated FN
15. Assessment
- FN is an oncologic emergency with mortality up to 11% overall and 50% in septic shock [3]
- Most patients (~60%) will have fever of unknown origin without an identifiable source; nonetheless, empiric treatment for bacterial infection is mandatory [1]
- Bacteremia is documented in ~20–30% of cases; most common organisms include coagulase-negative staphylococci, S. aureus, viridans streptococci, E. coli, Klebsiella, and Pseudomonas [1]
- Atypical presentations are the rule: Pneumonia without infiltrate, UTI without pyuria, soft tissue infection without purulence
- Complications: Septic shock, ARDS, DIC, typhlitis, invasive fungal disease
Severity stratification should guide site of care (inpatient vs. outpatient) and antibiotic route (IV vs. PO). [2]
16. Treatment Plan
Initial stabilization (ED)
- ABCs, IV access, fluid resuscitation if hypotensive
- Empiric antibiotics within 1 hour — do not wait for culture results or ANC confirmation [3][6]
- Antipyretics (acetaminophen preferred)
High-risk patients (inpatient IV therapy): [2]
Site-specific modifications: [2]
- Cellulitis/catheter infection → add vancomycin
- Vesicular lesions → add acyclovir
- Abdominal symptoms → ensure anaerobic coverage (carbapenems or pip/tazo preferred)
- Lung infiltrates → add atypical coverage (azithromycin or fluoroquinolone); consider antifungal if prolonged neutropenia [2]
- CNS symptoms → meropenem (Pseudomonas + Listeria coverage) + high-dose acyclovir [2]
Low-risk patients (outpatient oral therapy): [2]
- Ciprofloxacin + amoxicillin/clavulanate (category 1)
- Observe 2–12 hours before discharge; first dose in clinic/ED
- Daily monitoring for first 72 hours
Persistent fever ≥4–7 days on antibiotics: [2]
- Add empiric mold-active antifungal (voriconazole, liposomal amphotericin B, or echinocandin)
- Broaden antibacterial coverage based on clinical/microbiologic data
- Consider CT chest, abdomen, sinuses
- ID consultation
G-CSF: Consider therapeutic G-CSF (filgrastim 5 mcg/kg/day) in patients with risk factors for infection-associated complications (sepsis, age >65, ANC <100, expected neutropenia >10 days, pneumonia, invasive fungal infection). [7] G-CSF decreases hospitalization duration but has not demonstrated a mortality benefit. [4]
17. Disposition
Admission criteria (high risk — any one factor): [2]
- MASCC score <21 or CISNE ≥3
- Inpatient at fever onset
- Hemodynamic instability or clinically unstable
- Allogeneic HCT recipient
- Anticipated prolonged neutropenia (ANC ≤100 for ≥7 days)
- Hepatic insufficiency (aminotransferases >5× ULN) or renal insufficiency (CrCl <30)
- Uncontrolled/progressive cancer
- Pneumonia or complex infection at presentation
- Grade 3–4 mucositis
Discharge criteria (low risk): [2-3]
- MASCC ≥21, no high-risk features
- Outpatient at fever onset, ECOG 0–1
- Able to tolerate oral medications, no nausea/vomiting
- Adequate home environment: 24-hour caregiver, telephone, within ~1 hour of medical facility
- Patient/oncologist agreement with outpatient plan
- Observe 2–12 hours, administer first antibiotic dose, confirm stability before discharge
Readmission triggers: [3]
- Failure to defervesce after 2–3 days of oral antibiotics
- Recurrent fever after defervescence
- New signs/symptoms of infection
- Inability to tolerate oral medications
- Positive blood cultures with resistant organisms
18. Follow Up / Return Precautions
Follow-up timing: [2]
- Daily assessment (in-person or telephone) for first 72 hours
- If responding, daily telephone follow-up thereafter
- Monitor ANC and platelets for myeloid reconstitution
- Oncology follow-up within 48–72 hours
Return precautions — instruct patients to return immediately for: [2-3]
- Recurrent or persistent fever (≥38°C)
- New chills, rigors, or feeling worse
- Inability to eat, drink, or take medications
- New symptoms: cough, shortness of breath, abdominal pain, diarrhea, rash, confusion
- Catheter site redness, swelling, or drainage
Expected recovery: Most low-risk patients defervesce within 2–3 days. ANC recovery depends on chemotherapy regimen and G-CSF use. Antibiotics can typically be discontinued when ANC ≥500 and patient is afebrile for ≥48 hours; in patients who remain neutropenic but are afebrile and stable, de-escalation or discontinuation may be considered. [2]
References
1. Oncologic Emergencies: The Fever With Too Few Neutrophils. — Long B, Koyfman A. The Journal of Emergency Medicine. 2019.
2. Prevention and Treatment of Cancer-Related Infections. — Updated 2026-03-11. National Comprehensive Cancer Network.
3. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. — Taplitz RA, Kennedy EB, Bow EJ, et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2018.
4. Neutropenia: Evaluation and Management in the Primary Care Setting. — Kim MJ, Forlini C, Kremsreiter K. American Family Physician. 2025.
5. Pediatric Acute Lymphoblastic Leukemia. — Updated 2025-08-11. National Comprehensive Cancer Network.
6. Guideline for the Management of Fever and Neutropenia in Pediatric Patients With Cancer and Hematopoietic Cell Transplantation Recipients: 2023 Update. — Lehrnbecher T, Robinson PD, Ammann RA, et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2023.
7. Hematopoietic Growth Factors. — Updated 2025-12-05. National Comprehensive Cancer Network.